Positive top-line Phase III fasinumab results in osteoarthritis of the knee or hip

16 August 2018
2019_biotech_test_vial_discovery_big

Positive top-line results from a Phase III randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip have been released.

Israel’s Teva Pharmaceuticals Industries (NYSE: TEVA) and US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) are jointly developing fasinumab as part of a global collaboration agreement signed in September 2016.

Teva’s shares gained 3.66% to 8,361 shekels in Tel Aviv trading, while Regeneron edged up 2.03% to $369.20 by mid-morning in New York,

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology